This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone, ultrasound alone and the combination of both the multi-analyte blood test and ultrasound for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

The study population will consist of men and women age 21 to 84 (inclusive) who are at a high risk for HCC due to liver cirrhosis. This study population will be drawn from subjects that currently meet AASLD recommendations for HCC surveillance every 6 months by ultrasound. Subjects may be enrolled in an existing HCC surveillance program at the time of enrollment.

Primary disease category: Liver

Secondary disease categories: Cancer, Liver Cancer

This study is enrolling healthy volunteers.

Sponsor: Helio Health, Inc.

Protocol number: LAM-2018-01

Projected enrollment dates: February 2019 to August 2022

Official study title: Prospective Clinical Trial to Detect Liver Cancer Through Quantification of cfDNA Methylation in Blood Samples: A LAM Insight Trial Study